News
BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute
BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy candidates. Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies following some recent CureVac legal wins.
GlobalData on MSN1d
BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisitionBioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its ...
The major averages were mixed near noon with the Dow the laggard as a pullback in Boeing weighs on the Industrials index. U.S ...
BioNTech hat vereinbart, den ehemaligen Corona-Impfstoffkonkurrenten CureVac für rund 1,25 Milliarden Dollar (1,08 Milliarden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback